Gilead Sciences, Inc. (GILD)
156.04
-1.15
(-0.73%)
USD |
NASDAQ |
Oct 23, 16:00
156.41
+0.37
(+0.24%)
After-Hours: 20:00
Gilead Sciences Enterprise Value : 214.93B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 214.93B |
| October 22, 2026 | 216.35B |
| October 21, 2026 | 211.86B |
| October 20, 2026 | 215.51B |
| October 19, 2026 | 211.24B |
| October 16, 2026 | 215.11B |
| October 15, 2026 | 216.58B |
| October 14, 2026 | 211.82B |
| October 13, 2026 | 204.85B |
| October 12, 2026 | 207.96B |
| October 09, 2026 | 208.88B |
| October 08, 2026 | 203.83B |
| October 07, 2026 | 203.52B |
| October 06, 2026 | 200.27B |
| October 05, 2026 | 200.77B |
| October 02, 2026 | 200.90B |
| October 01, 2026 | 204.33B |
| September 30, 2026 | 206.25B |
| September 29, 2026 | 209.02B |
| September 28, 2026 | 210.17B |
| September 25, 2026 | 208.58B |
| September 24, 2026 | 207.05B |
| September 23, 2026 | 209.13B |
| September 22, 2026 | 210.74B |
| September 21, 2026 | 208.12B |
| Date | Value |
|---|---|
| September 18, 2026 | 207.57B |
| September 17, 2026 | 208.53B |
| September 16, 2026 | 204.55B |
| September 15, 2026 | 202.84B |
| September 14, 2026 | 202.97B |
| September 11, 2026 | 199.64B |
| September 10, 2026 | 200.99B |
| September 09, 2026 | 202.03B |
| September 08, 2026 | 203.26B |
| September 04, 2026 | 208.66B |
| September 03, 2026 | 208.94B |
| September 02, 2026 | 206.95B |
| September 01, 2026 | 207.33B |
| August 31, 2026 | 202.89B |
| August 28, 2026 | 202.07B |
| August 27, 2026 | 206.02B |
| August 26, 2026 | 205.06B |
| August 25, 2026 | 205.90B |
| August 24, 2026 | 203.38B |
| August 21, 2026 | 202.61B |
| August 20, 2026 | 199.29B |
| August 19, 2026 | 204.45B |
| August 18, 2026 | 199.29B |
| August 17, 2026 | 193.68B |
| August 14, 2026 | 192.98B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 569.05B |
| Vertex Pharmaceuticals, Inc. | 126.85B |
| Amgen, Inc. | 280.78B |
| Biogen, Inc. | 44.10B |
| Johnson & Johnson | 662.44B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.50B |
| Revenue (Quarterly) | 7.821B |
| Total Expenses (Quarterly) | 18.32B |
| EPS Diluted (Quarterly) | -8.444 |
| Gross Profit Margin (Quarterly) | 79.81% |
| Profit Margin (Quarterly) | -134.2% |
| Earnings Yield | -1.70% |
| Operating Earnings Yield | 6.11% |
| Normalized Earnings Yield | 3.045 |